--Dr. Sherman also elected President of the Drug Information Association (DIA)--

NORTHBROOK, Ill., June 29 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced the appointment of Jeffrey W. Sherman, M.D., F.A.C.P., as its executive vice president and chief medical officer.

Dr. Sherman brings more than 20 years of pharmaceutical experience to Horizon and will lead the regulatory and clinical strategy for Horizon's investigational therapies for mild-to-moderate arthritis and pain, including HZT-501, a fixed-dose combination tablet containing the most prescribed non-steroidal anti-inflammatory drug (NSAID), ibuprofen, with a high dose of the most potent H2 antagonist, famotidine. HZT-501 was shown to significantly reduce the incidence of NSAID-induced upper gastrointestinal ulcers in patients with mild-to-moderate pain in two Phase 3 studies.

Dr. Sherman joins Horizon from IDM Pharma, which was recently purchased by Takeda Pharmaceuticals Limited, where he led the clinical, regulatory, and development teams that secured European Commission approval for MEPACT(R) (mifamurtide, L-MTP-PE), a treatment for non-metastatic, resectable osteosarcoma. Prior to IDM Pharma, Dr. Sherman served as vice president of clinical science at Takeda Global Research & Development Center, Inc., a subsidiary of Takeda Pharmaceutical Company Limited, where he was focused on developing Takeda's oncology pipeline. Dr. Sherman also held the position of chief medical officer and executive vice president at NeoPharm, Inc., and held numerous research development and marketing roles at Searle/Pharmacia, including responsibility for the COX-2 (Celebrex) oncology program.

"Dr. Sherman has significant experience in the biotechnology and pharmaceutical industry, with a proven track record of success in bringing drugs through the regulatory process," said Timothy P. Walbert, president and chief executive officer of Horizon Therapeutics. "Dr. Sherman will oversee the preparation and submission of the HZT-501 regulatory applications to U.S. and European regulatory authorities, while helping us manage the clinical development of our other pain therapies."

In addition to his Horizon appointment, Dr. Sherman was recently elected President of the Drug Information Association (DIA), a global, nonprofit, multidisciplinary, professional association of approximately 18,000 members which provides a neutral forum for sharing information that optimizes the process of drug development and lifecycle management. He has been a member of the DIA Board of Directors for nearly seven years and in 2001, received the association's "Outstanding Service Award."

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy and patient compliance. For more information about the company and its products, please visit www.horizontherapeutics.com.

CONTACT: Robert De Vaere, Executive Vice President, Chief Financial
Officer of Horizon Therapeutics, Inc., +1-760-436-4010,
bdevaere@horizontherapeutics.com, or Carolyn Wang of WeissComm Partners,
+1-415-946-1065, cwang@wcpglobal.com, for Horizon Therapeutics, Inc.

Web site: http://www.horizontherapeutics.com/